<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160221026684N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-31</date_registration>
      <primary_sponsor>Behdane Baran Salem Abi</primary_sponsor>
      <public_title>The effect of cumin bread on blood sugar in type 2 diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of bread containing cumin on blood sugar in type 2 diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67438</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 60 patients with type 2 diabetes and meeting the inclusion criteria will be selected. After determining all available samples, stratified random allocation will be done in three layers of age, gender and average HbA1c. First, all patients are divided into two groups based on gender, and from both groups, an equal number of women will be placed in both the intervention and control groups, and an equal number of men will be placed in the intervention and control groups.
In the next step, all the patients who are assigned to two groups in terms of gender will be divided into four groups in terms of age and will be placed again in the intervention and control groups.
Finally, we will have two groups of patients with similar age and gender distribution for intervention and control.
Intervention allocation or random allocation is in the form of a closed envelope that the individual chooses before entering the researcher's room. The envelope with the letter A will be the intervention group and B will be the control group, Blinding description: In this study, only the main researchers are aware of the type of bread. The participating volunteers and other people involved in the project have no information about the type of bread. Both breads are similar in terms of shape, color, smell, packaging and appearance, and blinding has been done between them.</study_design>
      <phase>3</phase>
      <hc_freetext>Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group, it is recommended that the bread consumed by the diabetic patient should be cumin bread in all three meals and consume a total of 120 grams of cumin bread daily for 2 months (8 weeks). The bread consumed is delivered to the patient weekly. It was also emphasized to the study participants not to change their usual diet and physical activity level during the study period. Cumin bread: Bread made from wheat flour and cumin - the flour composition includes 96% wheat flour (with commercial name of Setareh) + 2% cumin powder + the remaining 2% includes yeast and permitted bread additives such as salt and standard ingredients that improve the quality of bread, which is converted into voluminous bread in the "Golnan Poratus" factory located in Karaj. Intervention 2: In the control group, it is recommended that the bread consumed by the diabetic patient be ordinary regular bread in all three meals and consume a total of 120 grams of this type of bread daily for 2 months (8 weeks). The bread consumed is delivered to the patient weekly. It was also emphasized to the study participants that they should not change their usual diet and physical activity level during the study period. ordinary bread:  made from wheat flour - the flour composition includes 98% wheat flour (with commercial name of Setareh) + the remaining 2% includes yeast and permitted bread additives such as salt and standard raw materials that improve the quality of the bread, which is converted into thick bread in the "Golnan Poratus" factory located in Karaj.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
HbA1c data : Data on the main outcome will be made available to other researchers with the permission of the first executor

When:
Starting one year after publication

To whom:
People working in academic institutions

Conditions:
Coordinate with project analyzer

Where to obtain:
Dr. Seyed ali Khodaie :03537280215 dr.seyedalikhodaie@yahoo.com

How to obtain:
Request data from Yazd University of Medical Sciences, approval of the director of the Diabetes Research Center, approval of the first executor of the project

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Ali Khodaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Shahid Sadoughi BLVD</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917693571</zip>
        <telephone>+98 35 3728 0215</telephone>
        <email>dr.seyedalikhodaie@yahoo.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Ali Khodaie</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>North Shahid Sadoughi blvd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917693571</zip>
        <telephone>+98 35 3728 0215</telephone>
        <email>dr.seyedalikhodaie@yahoo.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Type 2 diabetes
HbA1c&lt;9
At least 30 years old
A resident of Yazd
Absence of chronic systemic diseases</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Drug and alcohol addiction
Special diets
Special sports programs
Taking insulin
Creatinine above 1.2
Pregnancy or breastfeeding
Medical reasons (Chronic systemic diseases and mental-psychological diseases)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E08</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diabetes mellitus due to underlying condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group, it is recommended that the bread consumed by the diabetic patient should be cumin bread in all three meals and consume a total of 120 grams of cumin bread daily for 2 months (8 weeks). The bread consumed is delivered to the patient weekly. It was also emphasized to the study participants not to change their usual diet and physical activity level during the study period. Cumin bread: Bread made from wheat flour and cumin - the flour composition includes 96% wheat flour (with commercial name of Setareh) + 2% cumin powder + the remaining 2% includes yeast and permitted bread additives such as salt and standard ingredients that improve the quality of bread, which is converted into voluminous bread in the "Golnan Poratus" factory located in Karaj.</i_keyword>
      <i_keyword>In the control group, it is recommended that the bread consumed by the diabetic patient be ordinary regular bread in all three meals and consume a total of 120 grams of this type of bread daily for 2 months (8 weeks). The bread consumed is delivered to the patient weekly. It was also emphasized to the study participants that they should not change their usual diet and physical activity level during the study period. ordinary bread:  made from wheat flour - the flour composition includes 98% wheat flour (with commercial name of Setareh) + the remaining 2% includes yeast and permitted bread additives such as salt and standard raw materials that improve the quality of the bread, which is converted into thick bread in the "Golnan Poratus" factory located in Karaj.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HbA1c. Timepoint: At the beginning and end of the intervention (8 weeks after the start). Method of measurement: Chromatography (HPLC).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Serum triglyceride level. Timepoint: At the beginning and end of the intervention (8 weeks after the start). Method of measurement: Enzymatic method.</sec_outcome>
      <sec_outcome>Serum total cholesterol level. Timepoint: At the beginning and end of the intervention (8 weeks after the start). Method of measurement: Enzymatic method.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Behdane Baran Salem Abi</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-14</approval_date>
        <contact_name>Ethics committee of shahid sadoughi university of medical sciences</contact_name>
        <contact_address>Diabetes Research Center, Talar-e-Honar Alley, Shahid Sadoughi Blvd, Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
